27297608|t|Therapeutic Review of Methylprednisolone Acetate Intra-Articular Injection in the Management of Osteoarthritis of the Knee - Part 1: Clinical Effectiveness
27297608|a|Intra-articular (IA) corticosteroid injections are a common approach in the management of osteoarthritis (OA) of the knee. The effectiveness of injections and particular injection products is often discussed and debated in clinical arenas. The following therapeutic review examines the evidence for intra-articular methylprednisolone acetate (MPA) injections in the management of OA knee. A review of research evidence, published guidelines and clinical literature was undertaken following an electronic database and relevant literature search. The review found that there is limited evidence which indicates that a single dose intra-articular MPA injection can provide short to medium term benefits for pain, with less evidence for beneficial effects on function or stiffness. There is heterogeneity across studies and until recently, most studies had only short to medium term follow-up periods, thus limiting the evidence available on longer term benefit. There was also evidence indicating equivalent overall efficacy of MPA to that of other corticosteroid products. Most guideline recommendations concerning IA injections for OA knee have drawn on evidence from pooled data for several corticosteroid products. The review also found there was limited reporting of the incidence of adverse events in most studies. Overall, MPA shows efficacy for symptom relief in OA knee. At an individual management level, evidence for a limited duration of effect needs consideration in injections decisions. Furthermore, consensus across clinical guidelines suggests that the management of OA knee should be individualized to a person 's clinical history, degree of disability, risk factors, quality of life and personal preferences, whereby injecting involves a shared decision and forms part of a multimodal approach. Copyright Â© 2016 John Wiley & Sons Ltd.
27297608	0	11	Therapeutic	T169	C0302350
27297608	12	18	Review	T170	C0282443
27297608	22	74	Methylprednisolone Acetate Intra-Articular Injection	T121	C0309470
27297608	82	92	Management	T058	C0376636
27297608	96	122	Osteoarthritis of the Knee	T047	C0409959
27297608	133	155	Clinical Effectiveness	T080	C3850123
27297608	156	202	Intra-articular (IA) corticosteroid injections	T061	C2064783
27297608	216	224	approach	T082	C0449445
27297608	232	242	management	T058	C0376636
27297608	246	277	osteoarthritis (OA) of the knee	T047	C0409959
27297608	283	296	effectiveness	T080	C1280519
27297608	300	310	injections	T122	C1272883
27297608	326	335	injection	T122	C1272883
27297608	336	344	products	T071	C1514468
27297608	379	394	clinical arenas	T201	C0683325
27297608	410	421	therapeutic	T169	C0302350
27297608	422	428	review	T170	C0282443
27297608	442	450	evidence	T169	C0332120
27297608	455	470	intra-articular	T082	C0442108
27297608	471	514	methylprednisolone acetate (MPA) injections	T121	C0309470
27297608	522	532	management	T058	C0376636
27297608	536	543	OA knee	T047	C0409959
27297608	547	553	review	T170	C0282443
27297608	566	574	evidence	T169	C0332120
27297608	576	596	published guidelines	T170	C0936005
27297608	601	609	clinical	T080	C0205210
27297608	610	620	literature	T170	C0023866
27297608	649	668	electronic database	T170	C3841595
27297608	673	681	relevant	T080	C2347946
27297608	682	692	literature	T170	C0023866
27297608	693	699	search	T052	C1706202
27297608	705	711	review	T170	C0282443
27297608	740	748	evidence	T169	C0332120
27297608	772	783	single dose	T081	C0178602
27297608	784	799	intra-articular	T082	C0442108
27297608	800	813	MPA injection	T121	C0309470
27297608	847	855	benefits	T081	C0086387
27297608	860	864	pain	T184	C0030193
27297608	876	884	evidence	T169	C0332120
27297608	889	907	beneficial effects	T081	C0086387
27297608	911	919	function	T042	C1535551
27297608	923	932	stiffness	T184	C0162298
27297608	943	956	heterogeneity	T080	C0019409
27297608	1035	1052	follow-up periods	T058	C1522577
27297608	1072	1080	evidence	T169	C0332120
27297608	1106	1113	benefit	T081	C0086387
27297608	1130	1138	evidence	T169	C0332120
27297608	1169	1177	efficacy	T080	C1280519
27297608	1181	1184	MPA	T109,T121	C0600901
27297608	1202	1225	corticosteroid products	T109,T121,T125	C0443077
27297608	1232	1257	guideline recommendations	T170	C0681471
27297608	1269	1282	IA injections	T061	C0021488
27297608	1287	1294	OA knee	T047	C0409959
27297608	1309	1317	evidence	T169	C0332120
27297608	1347	1370	corticosteroid products	T109,T121,T125	C0443077
27297608	1376	1382	review	T170	C0282443
27297608	1429	1438	incidence	T081	C0021149
27297608	1442	1456	adverse events	T046	C0877248
27297608	1483	1486	MPA	T109,T121	C0600901
27297608	1493	1501	efficacy	T080	C1280519
27297608	1506	1513	symptom	T184	C1457887
27297608	1514	1520	relief	T061	C0451615
27297608	1524	1531	OA knee	T047	C0409959
27297608	1539	1549	individual	T098	C0237401
27297608	1550	1560	management	T058	C0376636
27297608	1561	1566	level	T080	C0441889
27297608	1568	1576	evidence	T169	C0332120
27297608	1633	1643	injections	T122	C1272883
27297608	1685	1704	clinical guidelines	T170	C0282451
27297608	1723	1733	management	T058	C0376636
27297608	1737	1744	OA knee	T047	C0409959
27297608	1755	1769	individualized	T080	C1881197
27297608	1775	1781	person	T098	C0237401
27297608	1785	1801	clinical history	T201	C1274016
27297608	1803	1809	degree	T081	C0449286
27297608	1813	1823	disability	T033	C0231170
27297608	1825	1837	risk factors	T033	C0035648
27297608	1839	1854	quality of life	T078	C0034380
27297608	1859	1879	personal preferences	T033	C1822123
27297608	1946	1965	multimodal approach	T061	C0871821